Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diapulmon is a topical and inhalation pharmaceutical product developed and marketed by **PannonPharma**. It is primarily indicated for the relief of symptoms associated with upper respiratory tract infections, including cough, nasal congestion, and bronchitis. The formulation typically exists as a hydrophilic ointment or inhalation drops containing a combination of active volatile substances, most notably **camphor**, **eucalyptus oil**, and **menthol**. These ingredients function as counter-irritants and mild expectorants; when applied topically to the chest or back, they provide a warming sensation and release vapors that, when inhaled, help to clear the airways and soothe respiratory irritation. The product is a well-established treatment in the Hungarian market.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Diapulmon.